Abstract
For most monoclonal antibodies (MAbs), preparation of research supplies is relatively straightforward. Cell culture is done by brute force, since little time is available to optimize product gene expression or cell growth. Systems that are often employed include: 1) suspension culture in spinner vessels, roller bottles or other containers, 2) ascites production in mice, and 3) hollow-fiber bioreactors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Center for Biologies Evaluation and Research (1994) Draft points to consider in the manufacturer and testing of monoclonal antibody products for human use. Rock ville, MD
Center for Biologies Evaluation and Research (1997) Points to consider in the manufacture and testing of monoclonal antibody products for human use. Rockville, MD
Committee on Proprietary Medical Products (1991) Note for guidance: Validation of virus removal and inactivation procedures. Brussels
Food and Drug Administration (1987) Guideline on validation of the Limulus amebocyte lysate test as an end-product endotoxin test for human and animal parenteral drugs, biological products, and medical devices. Rockville, MD
Horaud F (1991) Introductory remarks: Viral safety of biologicals. Develop Biol Standard 75: 3 – 7
International Conferences on Harmonization (1997) Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Geneva
Lubiniecki AS (1998) Process validation. Develop Biol Standard in press
Lubiniecki AS, May LH (1985) Cell bank characterization for recombinant DNA mammalian cell lines. Develop Biol Standard 60:141–146
Lubiniecki AS, McAllister PR, Smith TM, Shadle PJ (1996) Process evaluation for biopharmaceuticals: What is appropriate in process evaluation? Develop Biol Standard 88: 309 – 315
McAllister PR, Shadle PJ, Smith TM, Scott RG, Lubiniecki AS (1996) Use of a statistical strategy to evaluate sources of variability in viral safety experiments for a recombinant biopharmaceutical. Develop Biol Standard 88: 111 – 121
Shadle PJ, Erickson JC, Scott RG, Smith TM (1995) Antibody Purification. US Patent # 5,429, 756
World Health Organization Study Group (1987) Biologicals. Develop Biol Standard 68: 69 – 72
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lubiniecki, A.S. et al. (1999). Preparation of Clinical Trial Supplies of Biopharmaceuticals. In: Oxender, D.L., Post, L.E. (eds) Novel Therapeutics from Modern Biotechnology. Handbook of Experimental Pharmacology, vol 137. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59990-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-59990-3_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-65927-3
Online ISBN: 978-3-642-59990-3
eBook Packages: Springer Book Archive